Cambridge, Mass. — Vyome Holdings, Inc. announced that the China National Intellectual Property Administration has granted a patent covering formulation and therapeutic use claims for its proprietary besifloxacin topical gel program for inflammatory acne.
The clinical-stage biopharmaceutical company said Chinese Patent No. ZL 2021 1 0758695.X expands its intellectual property protection in China and could support future partnering, licensing and regional commercialization opportunities.
The patent includes claims related to the treatment of inflammatory acne, acne-associated inflammation and acne involving antibiotic-resistant Propionibacterium acnes. Vyome said China’s prescription acne market is projected to reach approximately $600 million annually by 2035.
Venkat Nelabhotla, Vyome Holdings Chief Executive Officer, said, “While VT-1953 for malignant fungating wounds remains our flagship program and the clear priority for our capital, clinical development, and execution efforts, we also believe it is important to continue strengthening our broader intellectual property portfolio in a highly capital-efficient manner. This newly granted Chinese patent further enhances our strategic optionality in the immuno-inflammation space without changing our operating priorities or requiring any significant incremental investment. We believe a strengthened intellectual property estate can support attractive partnering, licensing, and regional commercialization opportunities through predominantly non-dilutive pathways, allowing us to remain fully focused on advancing VT-1953 and building a leading immuno-inflammatory company while continuing to create value from our broader innovation portfolio.”
Vyome emphasized that VT-1953, its treatment candidate for malignant fungating wounds, remains its flagship program and primary capital allocation priority.
“Building durable intellectual property is fundamental to creating differentiated pharmaceutical innovation. This newly granted Chinese patent substantially strengthens our existing patent estate by adding meaningful formulation and therapeutic use protection around our proprietary besifloxacin topical platform. We believe that innovation extends well beyond the active pharmaceutical ingredient, and comprehensive intellectual property surrounding formulation science can create significant long-term value,” stated Dr. Shiladitya Sengupta, Vyome Co-Founder and Associate Professor of Medicine at Harvard Medical School.
